Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response in ... Business Wire (press release) Study 101-09 is a Phase 2, open-label, single-arm efficacy and safety study of idelalisib in patients with previously treated iNHL that is refractory both to rituximab and to alkylating-agent-containing chemotherapy (refractory defined as no response ... Gilead Reports Interim Results From Idelalisib Phase 2 Study - Quick Facts |
